[Significance of thrombus structure for the antithrombotic effectiveness of thrombocyte aggregation inhibiting substances and anticoagulants].
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001158:Arteries; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000032:analysis; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000494:pharmacology; D004338:Drug Combinations; D004912:Erythrocytes / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D013927:Thrombosis / Q000473:pathology*; D014680:Veins
D000925:Anticoagulants; D004338:Drug Combinations; D004176:Dipyridamole; D005340:Fibrinogen; D006493:Heparin; D001241:Aspirin
Die Bedeutung der Thrombusstruktur für die antithrombotische Wirksamkeit von thrombocytenaggregationshemmenden Substanzen und Antikoagulantien.